Becton, Dickinson (NYSE:BDX) is a New Jersey-based medical technology company. Its shares have climbed 3.5% year-over-year as of close on February 7.
The stock is worth a look today as it has achieved over 45 consecutive years of dividend growth. It is a dividend aristocrat today, and well on its way to being crowned a dividend king.
The company released its fiscal 2020 first-quarter results on February 6. Revenues rose 1.6% year-over-year to $4.22 billion.
It was forced to lowers its full fiscal year revenue and adjusted diluted earnings per share guidance due to delays on its software remediation plan for the Alaris System. The company is working to meet the Federal Drug Administration’s (FDA) expectations with the rollout.
It still projects that 2020 revenues will increase between 1.5% and 2.5% from the prior year and adjusted diluted earnings per share will post growth between 4% and 5.5%. These are still solid rates in a promising sector.
In addition to its promising earnings growth forecasts, the stock looks like a buy-the-dip candidate today. Its shares last had an RSI of 26, which puts it in technically oversold territory.
Becton Dickinson last reported a quarterly dividend of $0.77 per share. This represented its 46th straight year of dividend increases. It also means that Becton stock offers a modest 1.2% yield. Even still, I love its value after slipping following its most recent earnings report.
